日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Macrophage-rich niches regulate T cell dynamics at the liver invasive margin during gallbladder cancer progression

富含巨噬细胞的微环境在胆囊癌进展过程中调节肝脏侵袭边缘的T细胞动态。

Li, Maolan; Liu, Zhaonan; Shan, Shenbing; Jia, Ziyao; Li, Yongsheng; Liu, Fatao; Lu, Lina; Qiu, Shimei; Li, Chen; Wang, Ziyi; Yan, Siyuan; Zhao, Yuhao; Gao, Lili; Yuan, Zhiqing; Liu, Yuanding; Ma, Jiyao; Feng, Jiayi; Geng, Pengxiao; Li, Yiming; Xu, Xiaojing; Lin, Xinhua; Liu, Changjun; Liu, Zebing; Wu, Wenguang; Wu, Xiangsong; Gong, Wei; Li, Yanjing; Xiang, Dongxi; He, Yongning; Liu, Yun; Shao, Rong; Man, Kwan; Wei, Wu; Liu, Yingbin

Full-length transcriptome atlas of gallbladder cancer reveals trastuzumab resistance conferred by ERBB2 alternative splicing.

胆囊癌全长转录组图谱揭示了ERBB2选择性剪接赋予的曲妥珠单抗耐药性

Wang Ziyi, Gao Li, Jia Ziheng, Liu Liguo, Gu Ao, Liu Zhaonan, Zhu Qin, Zuo Yichen, Yang Mingjie, Wang Shijia, Ma Jiyao, Zhang Jingyun, Qiu Shimei, Li Zhizhen, Wang Jinghan, Xiang Dongxi, Liu Fatao, Shao Rong, Li Yanjing, Li Maolan, Wei Wu, Liu Yingbin

Targeted therapies and immunotherapies for unresectable cholangiocarcinoma

针对无法切除的胆管癌的靶向治疗和免疫疗法

Xue, Shengbai; Jiang, Weihua; Ma, Jingyu; Xu, Haiyan; Wang, Yanling; Lu, Wenxin; Shentu, Daiyuan; Cui, Jiujie; Li, Maolan; Wang, Liwei

Mitigating Postoperative Fistula Risks in Laparoscopic Pancreatic Enucleation: A Retrospective Study

降低腹腔镜胰腺剜除术后瘘管风险:一项回顾性研究

Li, Lin; Li, Xuechuan; Liu, Ke; Wu, Wenguang; Li, Maolan; Liu, Yingbin

Super-Enhancer Reprograming Driven by SOX9 and TCF7L2 Represents Transcription-Targeted Therapeutic Vulnerability for Treating Gallbladder Cancer

由SOX9和TCF7L2驱动的超级增强子重编程代表了治疗胆囊癌的转录靶向治疗弱点

Yan, Siyuan; Liu, Zhaonan; Wang, Teng; Sui, Yi; Wu, Xiangsong; Shen, Jiayi; Pu, Peng; Yang, Yang; Wu, Sizhong; Qiu, Shimei; Wang, Ziyi; Jiang, Xiaoqing; Feng, Feiling; Li, Guoqiang; Liu, FaTao; Zhao, Chaoxian; Liu, Ke; Feng, Jiayi; Li, Maolan; Man, Kwan; Wang, Chaochen; Tang, Yujie; Liu, Yingbin

Disease burden of biliary tract cancer in 204 countries and territories, 1990-2021: A comprehensive demographic analysis of the Global Burden of Disease Study 2021

1990-2021年204个国家和地区胆道癌的疾病负担:2021年全球疾病负担研究的综合人口统计分析

Sun, Xuheng; Liu, Jiangmei; Zhang, Wei; Wang, Yijun; Jiang, Yan; Wang, Lijun; Zou, Yixin; Xiao, Yuxuan; Xiang, Yongbing; Li, Maolan; Zhou, Maigeng; Liu, Yingbin

The footprint of gut microbiota in gallbladder cancer: a mechanistic review

肠道菌群在胆囊癌中的作用:机制综述

Liu, Shujie; Li, Weijian; Chen, Jun; Li, Maolan; Geng, Yajun; Liu, Yingbin; Wu, Wenguang

Afatinib in combination with GEMOX chemotherapy as the adjuvant treatment in patients with ErbB pathway mutated, resectable gallbladder cancer: study protocol for a ctDNA-based, multicentre, open-label, randomised, controlled, phase II trial

阿法替尼联合吉西他滨(GEMOX)化疗作为ErbB通路突变型可切除胆囊癌患者的辅助治疗:一项基于ctDNA的多中心、开放标签、随机、对照II期试验的研究方案

Yang, Mao; Zhao, Yuhao; Li, Yongsheng; Cui, Xuya; Liu, Fatao; Wu, Wenguang; Wang, Xu-An; Li, Maolan; Liu, Yun; Liu, Yingbin

Novel protein kinase inhibitor TT-00420 inhibits gallbladder cancer by inhibiting JNK/JUN-mediated signaling pathway.

新型蛋白激酶抑制剂 TT-00420 通过抑制 JNK/JUN 介导的信号通路来抑制胆囊癌。

Miao Huijie, Geng Yajun, Li Yang, Tang Shijie, Feng Feiling, Li Weijian, Li Yongsheng, Liu Liguo, Zhang Rui, Qiu Shimei, Wu Ying, Wang Zeyu, Wang Ziyi, Shao Ziyu, Liu Ke, Zou Lu, Yang Mao, Zhao Yuhao, Chen Chen, Li Zhizhen, Zhang Dadong, Peng Peng, Qiang Xiaoyan, Wu Frank, He Yongning, Chen Luonan, Xiang Dongxi, Jiang Xiaoqing, Li Maolan, Liu Yun, Liu Yingbin

Correction: EIF3D promotes gallbladder cancer development by stabilizing GRK2 kinase and activating PI3K-AKT signaling pathway

更正:EIF3D通过稳定GRK2激酶并激活PI3K-AKT信号通路促进胆囊癌的发生发展。

Zhang, Fei; Xiang, Shanshan; Cao, Yang; Li, Maolan; Ma, Qiang; Liang, Haibin; Li, Huaifeng; Ye, Yuanyuan; Zhang, Yijian; Jiang, Lin; Hu, Yunping; Zhou, Jian; Wang, Xuefeng; Zhang, Yong; Nie, Lei; Liang, Xiao; Gong, Wei; Liu, Yingbin